Abstract

Objective: This study aims to investigate the impact of P2RX5 on the clinical pathological characteristics and prognosis of endometrial carcinoma, and to explore its potential underlying mechanisms. Methods: The clinical samples, including 150 specimens with endometrial carcinoma (Case group) and 100 endometrial samples without cancer (Control group), were collected for analyzing the amount of P2RX5 expression. Cell biology experiments were also used for exploring the effects of P2RX5 expression on biological behaviors of endometrial carcinoma. Results: The results showed that P2RX5 expression in endometrial carcinoma tissues were significantly higher than in endometrial tissues from the control group. Additionally, expression levels showed a positive correlation with tumor size, differentiation grade, and tumor stage, with risk values of 3.57, 6.07, and 9.78, respectively. This increase in risk was statistically significant ( P < 0.001). Kaplan-Meier survival analysis demonstrated that increasing P2RX5 expression was associated with lower overall survival rates ( P < 0.05). Functional assays showed that knocking-down P2RX5 expression in the HEC-1B cell line significantly reduced the capacity of cell proliferation, migration, invasion, and clone formation. Following gene knockout, the rate of late apoptosis in tumor cells significantly increased ( P < 0.001), while the number of cells in the S phase and G2/M phase significantly decreased ( P < 0.05). Conclusion: These findings suggest a critical role of P2RX5 in endometrial cancer progression and thereby establish the value of P2RX5 as a prognostic biomarker and provide a promising therapeutic target for endometrial cancer treatment.